Conference coverage
Medical device hacking expert dies before releasing pacemaker exploit
Cybersecurity expert and avid medical device hacker Barnaby Jack died this week, just days before he was slated to present his latest research into hacking implantable cardiac devices.
Podcast: Medtronic CEO Omar Ishrak on emerging markets, economic value and the medtech tax
Europace: Boston Scientific touts new safety results for its lead-free S-ICD
Boston Scientific (NYSE:BSX) touted the results of a comparative analysis of patients treated with the subcutaneous implantable defibrillator, reporting that its lead-free ICD may be safer for patients.
St. Jude is “feeling really good” about Durata
Medical device maker St. Jude Medical (NYSE:STJ) is feeling pretty confident about public perception of its Durata defibrillator leads, which came under scrutiny amid a high-profile recall of its older Riata leads.
It’s not you, it’s me: Adventures in partnering at biotech conferences
EuroPCR: Volcano touts positive early results for its lesion assessment system
Volcano Corporation (NSDQ:VOLC) posted positive early findings for its instant wave-Free Ratio (iFR) coronary lesion detector, with results form its Advise II trial supporting results from older retrospective publications, according to a report unveiled during a hot line late-breaking clinical trial session at the EuroPCR meeting in Paris, France.
EuroPCR: 1-year results continue to support Edwards’ next-gen Sapien XT valve
EuroPCR: Boston Scientific’s Lotus TAVI bests rivals with less leakage
Massachusetts-based medical device titan Boston Scientific (NYSE:BSX) released early data from a study of its Lotus transcatheter aortic valve implantation system, highlighting very low rates of paravalvular leakage that analysts said could give the company some leverage in the highly charged TAVI market.
EuroPCR: Medtronic’s CoreValve is a cost-effective option, U.K. researchers say
The latest update from Medtronic’s (NYSE:MDT) ADVANCE registry of patients treated with the CoreValve transcatheter aortic valve implantation evaluated the technology from a cost perspective, with researchers reporting that CoreValve is worth the money for patients with severe aortic stenosis.